Tuis7CA • FRA
add
Camurus AB
Vorige sluiting
€53,10
Dagwisseling
€48,86 - €50,35
Jaarwisseling
€45,66 - €62,60
Markkapitalisasie
31,79 mjd SEK
Gemiddelde volume
16,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
STO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (SEK) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 558,34 m | 43,17% |
Bedryfskoste | 280,17 m | -0,10% |
Netto inkomste | 197,25 m | 153,33% |
Netto winsgrens | 35,33 | 76,92% |
Wins per aandeel | 3,29 | 149,24% |
EBITDA | 239,55 m | 190,91% |
Effektiewe belastingkoers | 22,33% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (SEK) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,88 mjd | 26,57% |
Totale bates | 3,97 mjd | 29,68% |
Totale aanspreeklikheid | 482,15 m | 16,16% |
Totale ekwiteit | 3,49 mjd | — |
Uitstaande aandele | 58,88 m | — |
Prys om te bespreek | 0,90 | — |
Opbrengs op bates | 15,46% | — |
Opbrengs op kapitaal | 17,31% | — |
Kontantvloei
Netto kontantverandering
| (SEK) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 197,25 m | 153,33% |
Kontant van bedrywe | 77,64 m | 113,70% |
Kontant van beleggings | -34,14 m | -1 992,16% |
Kontant van finansiering | -6,10 m | -100,58% |
Netto kontantverandering | 25,36 m | -97,66% |
Beskikbare kontantvloei | -47,50 m | -6 656,70% |
Meer oor
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Gestig
1991
Webwerf
Werknemers
265
